Work

Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors

Year: 2009

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2009.27.15_suppl.2559

Authors: C. R. Lindsay, E. Chan, T. R. Evans, S. Campbell, P. Bell, A. W. Stephens, A. Franke, S. Poondru, M. L. Rothenberg, I. Puzanov

Institutions: Beatson West of Scotland Cancer Centre, Cancer Research UK Scotland Institute, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Growth Hormone and Insulin-like Growth Factors

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2248901366

Cites:

Cited by: 20

Related to: 10